[Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma].

Yu lan Ren, Huaying Wang, Xiaoyan Zhou, Bo er Shan, Wentao Yang, Lei Shen, Da ren Shi

Research output: Contribution to journalArticle

Abstract

The purpose of this study was to evaluate gene amplification by chromogenic in situ hybridization (CISH) and the protein expression of Her-2/neu gene in patients with uterine papillary serous carcinoma (UPSC) and to determine its prognostic value. Thirty-six patients with confirmed pathologic diagnosis of UPSC in Cancer Hospital of Fudan University from Jan. 1996 to Jan. 2006, were analysed retrospectively. CISH was performed to assess Her-2/neu gene amplification, and protein expression was evaluated by immunohistochemistry (IHC). The prognostic factors were analyzed by log-rank test or Cox proportional hazard model. Among 36 cases with UPSC, 13 patients (36.1%) showed moderate staining (++) to strong staining (+++) for Her-2/neu protein, while amplification of the Her-2/neu gene by CISH was observed in 4 of the 36 (11.1%) cases. Her-2/neu protein over-expression was significantly associated with advanced surgical stage and worse prognosis by univariate analysis (P=0.030 and P=0.002, respectively), while the multivariate analysis shown that only Her-2/neu protein over-expression and deep myometrial invasion were associated with a poor prognosis (P<0.05). In 13 patients with Her-2/neu protein over-expression, the mean survival period with chemotherapy was shorter than those without chemotherapy (20 vs. 42 months, P=0.370). Her-2/neu protein over-expression is significantly associated with advanced surgical stage UPSC and poor survival outcome, and might reduce the chemotherapy sensitivity.

Original languageEnglish (US)
Pages (from-to)367-371
Number of pages5
JournalZhonghua fu chan ke za zhi
Volume45
Issue number5
StatePublished - Jan 1 2010

Fingerprint

Papillary Carcinoma
erbB-2 Genes
Proteins
In Situ Hybridization
Gene Amplification
Drug Therapy
Staining and Labeling
Cancer Care Facilities
Survival
Proportional Hazards Models
Multivariate Analysis
Immunohistochemistry

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma]. / Ren, Yu lan; Wang, Huaying; Zhou, Xiaoyan; Shan, Bo er; Yang, Wentao; Shen, Lei; Shi, Da ren.

In: Zhonghua fu chan ke za zhi, Vol. 45, No. 5, 01.01.2010, p. 367-371.

Research output: Contribution to journalArticle

@article{700783b75d85499996c954f11ff38636,
title = "[Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma].",
abstract = "The purpose of this study was to evaluate gene amplification by chromogenic in situ hybridization (CISH) and the protein expression of Her-2/neu gene in patients with uterine papillary serous carcinoma (UPSC) and to determine its prognostic value. Thirty-six patients with confirmed pathologic diagnosis of UPSC in Cancer Hospital of Fudan University from Jan. 1996 to Jan. 2006, were analysed retrospectively. CISH was performed to assess Her-2/neu gene amplification, and protein expression was evaluated by immunohistochemistry (IHC). The prognostic factors were analyzed by log-rank test or Cox proportional hazard model. Among 36 cases with UPSC, 13 patients (36.1{\%}) showed moderate staining (++) to strong staining (+++) for Her-2/neu protein, while amplification of the Her-2/neu gene by CISH was observed in 4 of the 36 (11.1{\%}) cases. Her-2/neu protein over-expression was significantly associated with advanced surgical stage and worse prognosis by univariate analysis (P=0.030 and P=0.002, respectively), while the multivariate analysis shown that only Her-2/neu protein over-expression and deep myometrial invasion were associated with a poor prognosis (P<0.05). In 13 patients with Her-2/neu protein over-expression, the mean survival period with chemotherapy was shorter than those without chemotherapy (20 vs. 42 months, P=0.370). Her-2/neu protein over-expression is significantly associated with advanced surgical stage UPSC and poor survival outcome, and might reduce the chemotherapy sensitivity.",
author = "Ren, {Yu lan} and Huaying Wang and Xiaoyan Zhou and Shan, {Bo er} and Wentao Yang and Lei Shen and Shi, {Da ren}",
year = "2010",
month = "1",
day = "1",
language = "English (US)",
volume = "45",
pages = "367--371",
journal = "Zhonghua fu chan ke za zhi",
issn = "0529-567X",
publisher = "Zhonghua Yixuehui Zazhishe",
number = "5",

}

TY - JOUR

T1 - [Clinical significance of Her-2/neu status in patients with uterine papillary serous carcinoma].

AU - Ren, Yu lan

AU - Wang, Huaying

AU - Zhou, Xiaoyan

AU - Shan, Bo er

AU - Yang, Wentao

AU - Shen, Lei

AU - Shi, Da ren

PY - 2010/1/1

Y1 - 2010/1/1

N2 - The purpose of this study was to evaluate gene amplification by chromogenic in situ hybridization (CISH) and the protein expression of Her-2/neu gene in patients with uterine papillary serous carcinoma (UPSC) and to determine its prognostic value. Thirty-six patients with confirmed pathologic diagnosis of UPSC in Cancer Hospital of Fudan University from Jan. 1996 to Jan. 2006, were analysed retrospectively. CISH was performed to assess Her-2/neu gene amplification, and protein expression was evaluated by immunohistochemistry (IHC). The prognostic factors were analyzed by log-rank test or Cox proportional hazard model. Among 36 cases with UPSC, 13 patients (36.1%) showed moderate staining (++) to strong staining (+++) for Her-2/neu protein, while amplification of the Her-2/neu gene by CISH was observed in 4 of the 36 (11.1%) cases. Her-2/neu protein over-expression was significantly associated with advanced surgical stage and worse prognosis by univariate analysis (P=0.030 and P=0.002, respectively), while the multivariate analysis shown that only Her-2/neu protein over-expression and deep myometrial invasion were associated with a poor prognosis (P<0.05). In 13 patients with Her-2/neu protein over-expression, the mean survival period with chemotherapy was shorter than those without chemotherapy (20 vs. 42 months, P=0.370). Her-2/neu protein over-expression is significantly associated with advanced surgical stage UPSC and poor survival outcome, and might reduce the chemotherapy sensitivity.

AB - The purpose of this study was to evaluate gene amplification by chromogenic in situ hybridization (CISH) and the protein expression of Her-2/neu gene in patients with uterine papillary serous carcinoma (UPSC) and to determine its prognostic value. Thirty-six patients with confirmed pathologic diagnosis of UPSC in Cancer Hospital of Fudan University from Jan. 1996 to Jan. 2006, were analysed retrospectively. CISH was performed to assess Her-2/neu gene amplification, and protein expression was evaluated by immunohistochemistry (IHC). The prognostic factors were analyzed by log-rank test or Cox proportional hazard model. Among 36 cases with UPSC, 13 patients (36.1%) showed moderate staining (++) to strong staining (+++) for Her-2/neu protein, while amplification of the Her-2/neu gene by CISH was observed in 4 of the 36 (11.1%) cases. Her-2/neu protein over-expression was significantly associated with advanced surgical stage and worse prognosis by univariate analysis (P=0.030 and P=0.002, respectively), while the multivariate analysis shown that only Her-2/neu protein over-expression and deep myometrial invasion were associated with a poor prognosis (P<0.05). In 13 patients with Her-2/neu protein over-expression, the mean survival period with chemotherapy was shorter than those without chemotherapy (20 vs. 42 months, P=0.370). Her-2/neu protein over-expression is significantly associated with advanced surgical stage UPSC and poor survival outcome, and might reduce the chemotherapy sensitivity.

UR - http://www.scopus.com/inward/record.url?scp=79953296308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953296308&partnerID=8YFLogxK

M3 - Article

C2 - 20646447

AN - SCOPUS:79953296308

VL - 45

SP - 367

EP - 371

JO - Zhonghua fu chan ke za zhi

JF - Zhonghua fu chan ke za zhi

SN - 0529-567X

IS - 5

ER -